Spruce Biosciences, Inc. (SPRB)

Market Cap	21.70M
Revenue (ttm)	10.13M
Net Income (ttm)	-46.75M
Shares Out	41.15M
EPS (ttm)	-1.13
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	256,378
Open	0.532
Previous Close	0.531
Day's Range	0.515 - 0.533
52-Week Range	0.503 - 5.950
Beta	2.49
Analysts	Hold
Price Target	2.50 (+374.11%)
Earnings Date	Aug 12, 2024

About SPRB

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric clas...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 9, 2020
• Employees: 22
• Stock Exchange: NASDAQ
• Ticker Symbol: SPRB

Analyst Forecast

According to 7 analysts, the average rating for SPRB stock is "Hold." The 12-month stock price forecast is $2.5, which is an increase of 374.11% from the latest price.

Price Target

$2.5

(374.11% upside)

Analyst Consensus: Hold